News | July 15, 2022
Syngene signs 10-year biologics manufacturing agreement with Zoetis
Syngene's collaboration with Zoetis started in 2011
Syngene's collaboration with Zoetis started in 2011
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Bringing next-gen cannabinoid therapeutics to cancer patients
Subscribe To Our Newsletter & Stay Updated
